AAAAAA

   
Results: 1-7 |
Results: 7
A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients
Authors: Villalona-Calero, MA Blum, JL Jones, SE Diab, S Elledge, R Khoury, P Von Hoff, D Kraynak, M Moczygemba, J Kromelis, P Griffin, T Rowinsky, EK
Citation: Ma. Villalona-calero et al., A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients, ANN ONCOL, 12(5), 2001, pp. 605-614
Effect of telomere and telomerase interactive agents on human tumor and normal cell lines
Authors: Rha, SY Izbicka, E Lawrence, R Davidson, K Sun, DK Moyer, MP Roodman, GD Hurley, L Von Hoff, D
Citation: Sy. Rha et al., Effect of telomere and telomerase interactive agents on human tumor and normal cell lines, CLIN CANC R, 6(3), 2000, pp. 987-993
MGI 114: Augmentation of antitumor activity when combined with topotecan
Authors: Weitman, S Barrera, H Moore, R Gonzalez, C Marty, J Hilsenbeck, S MacDonald, JR Waters, SJ Von Hoff, D
Citation: S. Weitman et al., MGI 114: Augmentation of antitumor activity when combined with topotecan, J PED H ONC, 22(4), 2000, pp. 306-314
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
Authors: Nemunaitis, J Holmlund, JT Kraynak, M Richards, D Bruce, J Ognoskie, N Kwoh, TJ Geary, R Dorr, A Von Hoff, D Eckhard, SG
Citation: J. Nemunaitis et al., Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer, J CL ONCOL, 17(11), 1999, pp. 3586-3595
American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants
Authors: Hensley, ML Schuchter, LM Lindley, C Meropol, NJ Cohen, GI Broder, G Gradishar, WJ Green, DM Langdon, RJ Mitchell, B Negrin, R Szatrowski, TP Thigpen, JT Von Hoff, D Wasserman, TH Winer, EP Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft
Authors: Weitman, S Mangold, G Marty, J Dexter, D Hilsenbeck, S Rake, J Juniewicz, P Von Hoff, D
Citation: S. Weitman et al., Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft, CANC CHEMOT, 43(5), 1999, pp. 402-408
Comparison of in vitro activities of camptothecin and nitidine derivativesagainst fungal and cancer cells
Authors: Del Poeta, M Chen, SF Von Hoff, D Dykstra, CC Wani, MC Manikumar, G Heitman, J Wall, ME Perfect, JR
Citation: M. Del Poeta et al., Comparison of in vitro activities of camptothecin and nitidine derivativesagainst fungal and cancer cells, ANTIM AG CH, 43(12), 1999, pp. 2862-2868
Risultati: 1-7 |